Abstract
The motor symptoms of Parkinson’s disease (PD) are due primarily to the degeneration of the dopaminergic nigrostriatal pathway; however other neurotransmitters besides dopamine are affected in the disease. Treatment of PD is largely unsatisfactory due to several side effects such as “on/off,” “wearing-off,” and dyskinesia, associated with dopaminergic chronic therapy. Therefore, new pharmacological approaches based on non-dopaminergic therapy have been recently called for a broadening of therapeutic options beyond traditional dopaminergic drugs. Adenosine A2A receptors have a selective localization in richly dopamine-innervated areas and A2A receptor antagonists can regulate GABA and glutamate release in basal ganglia offering a unique opportunity to modulate basal ganglia functions mediated by dopamine. Indeed, A2A receptor antagonists have been shown to restore motor function and contrast parkinsonian tremor acutely, either alone or in combination with dopaminergic drugs, in experimental models of PD. Moreover, in clinical trials, adenosine A2A receptor antagonists reduce “off” time in patients with PD receiving optimal dopaminergic therapy without the exacerbation of dyskinesia. In addition preclinical data have shown that adenosine A2A receptor antagonists help to prevent neurodegeneration in PD, raising the possibility of their use as disease-modifying agents. With their proposed symptomatic and neuroprotective efficacy, A2A receptor antagonists might be realistic prospects to advance PD therapeutics.
Keywords
Annalisa Pinna and Nicola Simola have contributed equally to this work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- A2AR:
-
A2A receptors
- AMP:
-
Adenosine monophosphate
- ATP:
-
Adenosine triphosphate
- CPu:
-
Caudate–putamen
- CSF:
-
Cerebrospinal fluid
- DDS:
-
Dopamine-dysregulation syndrome
- FDA:
-
Food and drug administration
- GAD67:
-
Glutamic acid decarboxylase 67
- GP:
-
Globus pallidus
- 6-OHDA:
-
6-hydroxydopamine
- l-DOPA:
-
Levo-DOPA
- MDMA:
-
3,4-methylenedioxymethamphetamine
- mGlu5:
-
Metabotropic glutamate receptor 5
- MPTP:
-
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- PD:
-
Parkinson’s disease
- PET:
-
Positron emission tomography
- SNr:
-
Substantia nigra pars reticulata
- TJMs:
-
Tremulous jaw movements
- VEGF:
-
Vascular endothelial growth factor
- UPDRS:
-
Unified PD Rating Scale
References
Adair TH (2005) Growth regulation of the vascular system: an emerging role for adenosine. Am J Physiol Regul Integr Comp Physiol 289:R283–R296
Alfinito PD, Wang SP, Manzino L, Rijhsinghani S, Zeevalk GD, Sonsalla PK (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23:10982–10987
Alonso A, Rodríguez LA, Logroscino G, Hernán MA (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696–1700
Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K (2008) Uric acid associates with cognition in Parkinson’s disease. Parkinsonism Relat Disord 14:576–578
Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460–1468
Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology 61:293–296
Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 184:285–294
Black KJ, Campbell MC, Dickerson W, Creech ML, Koller JM, Chung S, Bandak SI (2010) A randomized, double-blind, placebo-controlled cross-over trial of the adenosine A2A antagonist SYN115 in Parkinson disease. Neurology 74(Suppl 2):A317
Bové J, Serrats J, Mengod G, Cortés R, Tolosa E, Marin C (2005) Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res 165:362–374
Bové J, Serrats J, Mengod G, Cortés R, Aguilar E, Marin C (2006) Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse 59:435–444
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Brooks DJ, Warrington S, Tendolkar A, Cutler DL, Hunter J (2009) Positron emission tomography (PET) study of preladenant in healthy male subjects. Mov Disord 24(suppl 1):S257
Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, O’Neill G (2010) An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 33:55–60
Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson’s disease patients with dyskinesias. Brain 127:1075–1084
Camarasa J, Pubill D, Escubedo E (2006) Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res 1111:72–82
Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F et al (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32:2249–2259
Carta AR, Pinna A, Cauli O, Morelli M (2002) Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-DOPA and A2A receptor blockade plus L-DOPA in dopamine-denervated rats. Synapse 44:166–174
Carta AR, Fenu S, Pala P, Tronci E, Morelli M (2003) Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 18:2563–2572
Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M (2009) Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson’s disease. J Neurochem 111:1478–1489
Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD (2003) Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 61:S107–S111
Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192–9200
Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ et al (2001a) The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 98:1970–1975
Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA (2001b) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 21:RC143
Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33:419–425
Cipriani S, Chen X, Schwarzschild MA (2010) Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 4:701–712
Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J et al (2006) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26:2080–2087
Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29:1451–1461
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909
Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR et al (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9:251–259
De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H (2008) Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum 59:1549–1554
Derlet RW, Tseng JC, Albertson TE (1992) Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am J Emerg Med 10:211–216
Deussen A, Brand M, Pexa A, Weichsel J (2006) Metabolic coronary flow regulation—current concepts. Basic Res Cardiol 101:453–464
El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM (2001) Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 134:68–77
Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM (2010) A long-term study of istradefylline in subjects with fluctuating Parkinson’s disease. Parkinsonism Relat Disord 16:423–426
Fenu S, Pinna A, Ongini E, Morelli M (1997) Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143–147
Fenu S, Wardas J, Morelli M (2009) Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson’s disease. Behav Pharmacol 20:363–379
Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM (2010) Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 16:16–20
Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482–487
Ferré S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casadó V, Fuxe K, Goldberg SR, Lluis C et al (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940–11945
Frau L, Borsini F, Wardas J, Khairnar AS, Schintu N, Morelli M (2011) Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson’s disease. Synapse 65:181–188
Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51(1):83–133
Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A (2008) Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 167:831–838
Gevaerd MS, Takahashi RN, Silveira R, Da Cunha C (2001) Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 55:101–106
Giménez-Llort L, Schiffmann SN, Shmidt T, Canela L, Camón L, Wassholm M, Canals M, Terasmaa A, Fernández-Teruel A, Tobeña A et al (2007) Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol Learn Mem 87:42–56
Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673–1677
Hauser RA, Shulman LM, Trugman JM, Roberts J, Mori A, Ballerini R, Sussman NM (2008) Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 23:2177–2185
Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K (2011) Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221–229
Hershfield MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35:25–30
Hettinger BD, Lee A, Linden J, Rosin DL (2001) Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431:331–346
Higgins GA, Grzelak ME, Pond AJ, Cohen-Williams ME, Hodgson RA, Varty GB (2007) The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors. Behav Brain Res 185:32–42
Higley MJ, Sabatini BL (2010) Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13:958–966
Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J et al (2002) Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 77:18091–18097
Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, Cohen-Williams ME, Higgins GA, Impagnatiello F, Nicolussi E et al (2009) Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 in rodent models of movement disorders and depression. J Pharmacol Exp Ther 330:294–303
Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, Pond AJ, Hadjtahar A, Belanger N, Gregoire L et al (2010) Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 225:384–390
Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O (2005) Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 8:858–859
Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 53:S49–S58
Ikeda K, Kurokawa M, Aoyama S, Kuwana Y (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem 80:262–270
Jellinger KA (2002) Recent developments in the pathology of Parkinson’s disease. J Neural Transm Suppl 62:347–376
Jenner P (2005) Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin Investig Drugs 14:729–738
Jenner P, Marsden CD (1986) The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson’s disease. J Neural Transm Suppl 20:11–39
Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25:10414–10419
Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (1998a) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507–513
Kanda T, Tashiro T, Kuwana Y, Jenner P (1998b) Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9:2857–2860
Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321–327
Kerschensteiner M, Meinl E, Hohlfeld R (2009) Neuro-immune crosstalk in CNS diseases. Neuroscience 158:1122–1132
Khairnar A, Plumitallo A, Frau L, Schintu N, Morelli M (2010) Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain. Neurotox Res 17:435–439
Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, Miyauchi S, Kamo N, Kishi T (2007) Interactions between 3,4-methylenedioxymethamphetamine, methamphetamine, ketamine, and caffeine in human intestinal Caco-2 cells and in oral administration to rats. Forensic Sci Int 170:183–188
Lane EL, Cheetham SC, Jenner P (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson’s disease? Exp Neurol 197:284–290
Lange KW, Riederer P (1994) Glutamatergic drugs in Parkinson’s disease. Life Sci 55:2067–2075
Lazarus M, Shen HY, Cherasse Y, Qu WM, Huang ZL, Bass CE, Winsky-Sommerer R, Semba K, Fredholm BB, Boison D, Hayaishi O, Urade Y, Chen JF (2011) Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci 6:10067–10075
LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM (2008) Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces OFF time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63:295–302
Lopes LV, Cunha RA, Ribeiro JA (1999) Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J Neurophysiol 82:3196–3203
Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M (2004) Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 173:21–24
Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398–1410
Masino SA, Dulla CG (2005) Adenosine, glutamate and pH: interactions and implications. Neurol Res 27:149–152
McNamara R, Kerans A, O’Neill B, Harkin A (2006) Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (“Ecstasy”) and MDA (“Love”). Neuropharmacology 50:69–80
McNamara R, Maginn M, Harkin A (2007) Caffeine induces a profound and persistent tachycardia in response to MDMA (“Ecstasy”) administration. Eur J Pharmacol 555:194–198
Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord 25:1437–1443
Morelli M, Carta AR, Kachroo A, Schwarzschild MA (2010) Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res 183:183–208
Nishi A, Liu F, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc Natl Acad Sci USA 100:1322–1327
O’Neill M, Brown VJ (2006) The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology (Berl) 184:46–55
Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW (2000) Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci 23:S8–S19
Oh JD, Chase TN (2002) Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson’s disease. Amino Acids 23:133–139
Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920
Pierri M, Vaudano E, Sager T, Englund U (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517–524
Pinna A (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Investig Drugs 18:1619–1631
Pinna A, Di Chiara G, Wardas J, Morelli M (1996) Blockade of A2A adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 8:1176–1181
Pinna A, Fenu S, Morelli M (2001) Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233–238
Pinna A, Volpini R, Cristalli G, Morelli M (2005) New adenosine A2A receptor antagonists: actions on Parkinson’s disease models. Eur J Pharmacol 512:157–164
Pinna A, Pontis S, Morelli M (2006) Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res 171:175–178
Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M (2010) A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58:613–623
Popoli P, Minghetti L, Tebano MT, Pintor A, Domenici MR, Massotti M (2004) Adenosine A2A receptor antagonism and neuroprotection: mechanisms, lights, and shadows. Crit Rev Neurobiol 16:99–106
Quarta D, Ferré S, Solinas M, You ZB, Hockemeyer J, Popoli P, Goldberg SR (2004) Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens: effects of chronic caffeine exposure. J Neurochem 88:1151–1158
Ritchie K, Carrière I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 69:536–545
Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P (2006) The novel adenosine A2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 546:82–87
Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674–2679
Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591–611
Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (2007) Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83:277–292
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Parkinson Study Group PRECEPT Investigators et al (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65:716–723
Shah U, Hodgson R (2010) Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson’s disease. Curr Opin Drug Discov Devel 13:466–480
Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (2004) Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189:182–188
Soriano A, Ventura R, Molero A, Hoen R, Casadó V, Cortés A, Fanelli F, Albericio F, Lluís C, Franco R et al (2009) Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J Med Chem 52:5590–5602
Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM (2008) A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70:2233–2240
Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P, Ghirardi O, Carminati P (2006) ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol 9:575–584
Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13:2614–2632
Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M (2007) Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol 566:94–102
Vanattou-Saïfoudine N, Gossen A, Harkin A, Neuropsychopharmacology Research Group (2011) A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA “Ecstasy”-induced striatal dopamine release. Eur J Pharmacol 650:220–228
Wang JH, Ma YY, van den Buuse M (2006) Improved spatial recognition memory in mice lacking adenosine A2A receptors. Exp Neurol 199:438–445
Wang XJ, Luo WF, Wang LJ, Mao CJ, Wang L, Liu CF (2009) Study on uric acid and the related factors associated with cognition in the patients with Parkinson’s disease. Zhonghua Yi Xue Za Zhi 89:1633–1635
Wardas J, Konieczny J, Lorenc-Koci E (2001) SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41:160–171
Wei CJ, Singer P, Coelho J, Boison D, Feldon J, Yee BK, Chen JF (2011) Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Mem 18:459–474
Yu L, Shen HY, Coelho JE, Araújo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J et al (2008) Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338–346
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pinna, A., Simola, N., Frau, L., Morelli, M. (2013). Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease. In: Masino, S., Boison, D. (eds) Adenosine. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3903-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3903-5_18
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3902-8
Online ISBN: 978-1-4614-3903-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)